What is Acorda Therapeutics Forward Dividend Yield %?
As of today (2024-06-07), the Forward Annual Dividend Yield of Acorda Therapeutics is 0.00%.
As of today (2024-06-07), the Trailing Annual Dividend Yield of Acorda Therapeutics is 0.00%.
ACORQ's Forward Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.945 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Competitive Comparison of Acorda Therapeutics's Forward Dividend Yield %
For the Drug Manufacturers - Specialty & Generic subindustry, Acorda Therapeutics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acorda Therapeutics's Forward Dividend Yield % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Acorda Therapeutics's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Acorda Therapeutics's Forward Dividend Yield % falls into.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Acorda Therapeutics Forward Dividend Yield % Related Terms
Thank you for viewing the detailed overview of Acorda Therapeutics's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Acorda Therapeutics (Acorda Therapeutics) Business Description
Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ACORQ has been successfully added to your